As a result, SGLT2 inhibitors are now recommended as first add-on (or even first-line, alongside metformin) when someone has established cardiovascular disease, heart failure, or chronic kidney disease: even if their HbA1c is at target
10.1371/journal.pone.0103443 2 AshrafiG.SchwarzT
doi: 10.1016/j.hsr.2023.100138 102
While not a one-size-fits-all solution, GLP-1RAs could offer new hope for those struggling with fatigue, MCAS, and other chronic conditions
Probiotics and non-alcoholic fatty liver disease: unveiling the mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in modulating lipid metabolism, inflammation, and intestinal barrier integrity
For years, the idea of activating glucagon receptors for weight loss seemed counterintuitive since glucagon raises blood sugar